metformin has been researched along with Amentia in 26 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia." | 8.98 | Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018) |
| "Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence." | 8.31 | Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study. ( Chan, L; Chen, PC; Chen, WT; Chien, LN; Hong, CT, 2023) |
| "Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI." | 8.12 | Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022) |
| "Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset." | 8.12 | Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. ( Albers, MW; Betensky, RA; Blacker, D; Boswell, S; Charpignon, ML; Das, S; Evans, K; Finkelstein, SN; Hyman, BT; Magdamo, C; Middleton, L; Rodriguez, S; Sheu, YH; Sokolov, A; Somai, M; Su, B; Tzoulaki, I; Vakulenko-Lagun, B; Welsch, RE; Zheng, B, 2022) |
| "Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug." | 7.96 | Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. ( Barthold, D; Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF; Zubatsky, M, 2020) |
| "The aim of this study is to investigate the association between metformin usage and dementia in an elderly Korean population." | 7.96 | Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, HC; Lee, JW; You, HS, 2020) |
| " Metformin use has been associated with a lower risk of dementia compared with sulfonylureas." | 7.91 | Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019) |
| " Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively." | 7.91 | Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019) |
| "To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia." | 7.91 | Metformin and Sulfonylurea Use and Risk of Incident Dementia. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019) |
| "The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy." | 7.88 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 7.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| "This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia." | 7.85 | Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. ( Cho, K; Cormack, J; Driver, JA; Gagnon, DR; Orkaby, AR, 2017) |
| "Long-term use of pioglitazone was associated with a lower dementia incidence." | 7.81 | Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015) |
| "Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)." | 7.01 | Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023) |
| "Dementia was ascertained by ICD9-CM or A-code." | 6.76 | Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. ( Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011) |
| "This analysis indicated that patients with type 2 diabetes under treatment with DPP-4 inhibitors presented with the lowest risk of dementia, followed by those treated with metformin and thiazolidinedione, while treatment with insulin was associated with the highest risk." | 5.05 | Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. ( Han, M; Simó, R; Tang, X; Yang, J; Zhou, JB, 2020) |
| "To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia." | 4.98 | Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018) |
| "Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence." | 4.31 | Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study. ( Chan, L; Chen, PC; Chen, WT; Chien, LN; Hong, CT, 2023) |
| "Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset." | 4.12 | Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. ( Albers, MW; Betensky, RA; Blacker, D; Boswell, S; Charpignon, ML; Das, S; Evans, K; Finkelstein, SN; Hyman, BT; Magdamo, C; Middleton, L; Rodriguez, S; Sheu, YH; Sokolov, A; Somai, M; Su, B; Tzoulaki, I; Vakulenko-Lagun, B; Welsch, RE; Zheng, B, 2022) |
| "Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI." | 4.12 | Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022) |
| "Dual therapy with metformin (Met) + dipeptidyl peptidase-4 inhibitor (DPP-4i), Met + thiazolidinedione (TZD), and sulfonylurea (SU) + thiazolidinediones (TZD) were significantly associated with all-cause dementia (HR = 0." | 4.02 | The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study. ( Han, K; Kim, WJ; Noh, JH; Park, CY, 2021) |
| "The aim of this study is to investigate the association between metformin usage and dementia in an elderly Korean population." | 3.96 | Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, HC; Lee, JW; You, HS, 2020) |
| "Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug." | 3.96 | Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. ( Barthold, D; Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF; Zubatsky, M, 2020) |
| " Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively." | 3.91 | Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019) |
| " Metformin use has been associated with a lower risk of dementia compared with sulfonylureas." | 3.91 | Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019) |
| "To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia." | 3.91 | Metformin and Sulfonylurea Use and Risk of Incident Dementia. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019) |
| "001, 95% CI) with age, dementia, changes in blood red cell counts, memory, and with the taking of metformin and proton pump inhibitors (P=." | 3.88 | [Vitamin B ( Camarero-Shelly, M, 2018) |
| "The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy." | 3.88 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 3.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| "To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality." | 3.85 | Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. ( Espinoza, SE; Habib, SL; Jo, B; Lorenzo, C; Wang, CP, 2017) |
| "This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia." | 3.85 | Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. ( Cho, K; Cormack, J; Driver, JA; Gagnon, DR; Orkaby, AR, 2017) |
| "Long-term use of pioglitazone was associated with a lower dementia incidence." | 3.81 | Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015) |
| "Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)." | 3.01 | Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023) |
| "Dementia was ascertained by ICD9-CM or A-code." | 2.76 | Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. ( Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011) |
| "Insulin resistance is considered to play an important role in the associations between DM and dementia." | 2.53 | Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis. ( Luo, YJ; Xiao, J; Ye, F; Yi, G; Yu, NW, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 14 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaei Malazy, O | 1 |
| Bandarian, F | 1 |
| Qorbani, M | 1 |
| Mohseni, S | 1 |
| Mirsadeghi, S | 1 |
| Peimani, M | 1 |
| Larijani, B | 1 |
| Wu, CY | 1 |
| Shapiro, L | 1 |
| Ouk, M | 1 |
| MacIntosh, BJ | 1 |
| Black, SE | 1 |
| Shah, BR | 1 |
| Swardfager, W | 1 |
| Newby, D | 1 |
| Linden, AB | 1 |
| Fernandes, M | 1 |
| Molero, Y | 1 |
| Winchester, L | 1 |
| Sproviero, W | 1 |
| Ghose, U | 1 |
| Li, QS | 1 |
| Launer, LJ | 2 |
| Duijn, CMV | 1 |
| Nevado-Holgado, AJ | 1 |
| Charpignon, ML | 2 |
| Vakulenko-Lagun, B | 2 |
| Zheng, B | 2 |
| Magdamo, C | 2 |
| Su, B | 2 |
| Evans, K | 2 |
| Rodriguez, S | 2 |
| Sokolov, A | 2 |
| Boswell, S | 2 |
| Sheu, YH | 2 |
| Somai, M | 2 |
| Middleton, L | 2 |
| Hyman, BT | 2 |
| Betensky, RA | 2 |
| Finkelstein, SN | 2 |
| Welsch, RE | 2 |
| Tzoulaki, I | 2 |
| Blacker, D | 2 |
| Das, S | 2 |
| Albers, MW | 2 |
| Chen, PC | 1 |
| Hong, CT | 1 |
| Chen, WT | 1 |
| Chan, L | 1 |
| Chien, LN | 1 |
| Tahmi, M | 1 |
| Luchsinger, JA | 1 |
| Fyfe, I | 1 |
| Salas, J | 3 |
| Morley, JE | 3 |
| Scherrer, JF | 3 |
| Floyd, JS | 3 |
| Farr, SA | 3 |
| Zubatsky, M | 1 |
| Barthold, D | 1 |
| Dublin, S | 3 |
| Zhou, JB | 1 |
| Tang, X | 1 |
| Han, M | 1 |
| Yang, J | 1 |
| Simó, R | 1 |
| Secnik, J | 1 |
| Xu, H | 1 |
| Schwertner, E | 1 |
| Hammar, N | 1 |
| Alvarsson, M | 1 |
| Winblad, B | 1 |
| Eriksdotter, M | 1 |
| Garcia-Ptacek, S | 1 |
| Religa, D | 1 |
| Kim, Y | 1 |
| Kim, HS | 1 |
| Lee, JW | 1 |
| Kim, YS | 1 |
| You, HS | 1 |
| Bae, YJ | 1 |
| Lee, HC | 1 |
| Han, YE | 1 |
| Choi, EA | 1 |
| Kim, J | 1 |
| Kang, HT | 1 |
| Violante-Cumpa, JR | 1 |
| Pérez-Arredondo, LA | 1 |
| González-González, JG | 1 |
| Mancillas-Adame, LG | 1 |
| Samaras, K | 1 |
| Crawford, JD | 1 |
| Draper, B | 1 |
| Trollor, JN | 1 |
| Brodaty, H | 1 |
| Sachdev, PS | 1 |
| Kim, WJ | 1 |
| Noh, JH | 1 |
| Han, K | 1 |
| Park, CY | 1 |
| Camarero-Shelly, M | 1 |
| Kenawy, S | 1 |
| Hegazy, R | 1 |
| Hassan, A | 1 |
| El-Shenawy, S | 1 |
| Gomaa, N | 1 |
| Zaki, H | 1 |
| Attia, A | 1 |
| Orkaby, AR | 1 |
| Cho, K | 1 |
| Cormack, J | 1 |
| Gagnon, DR | 1 |
| Driver, JA | 1 |
| Lu, CH | 1 |
| Yang, CY | 1 |
| Li, CY | 1 |
| Hsieh, CY | 1 |
| Ou, HT | 1 |
| Campbell, JM | 1 |
| Stephenson, MD | 1 |
| de Courten, B | 1 |
| Chapman, I | 1 |
| Bellman, SM | 1 |
| Aromataris, E | 1 |
| Weinstein, G | 1 |
| Davis-Plourde, KL | 1 |
| Conner, S | 1 |
| Himali, JJ | 1 |
| Beiser, AS | 1 |
| Lee, A | 1 |
| Rawlings, AM | 1 |
| Sedaghat, S | 1 |
| Ding, J | 1 |
| Moshier, E | 1 |
| van Duijn, CM | 1 |
| Beeri, MS | 1 |
| Selvin, E | 1 |
| Ikram, MA | 1 |
| Haan, MN | 1 |
| Seshadri, S | 1 |
| Heneka, MT | 1 |
| Fink, A | 1 |
| Doblhammer, G | 1 |
| Ye, F | 1 |
| Luo, YJ | 1 |
| Xiao, J | 1 |
| Yu, NW | 1 |
| Yi, G | 1 |
| Wang, CP | 1 |
| Lorenzo, C | 1 |
| Habib, SL | 1 |
| Jo, B | 1 |
| Espinoza, SE | 1 |
| Hsu, CC | 1 |
| Wahlqvist, ML | 1 |
| Lee, MS | 1 |
| Tsai, HN | 1 |
6 reviews available for metformin and Amentia
| Article | Year |
|---|---|
The effect of metformin on cognitive function: A systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Disease Progression; Humans; Metformi | 2022 |
Glucose-lowering drugs, cognition, and dementia: The clinical evidence.
Topics: Cognition; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; | 2022 |
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias.
Topics: Alzheimer Disease; Animals; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2023 |
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Topics: Bayes Theorem; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypo | 2020 |
Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.
Topics: Cognitive Dysfunction; Dementia; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents | 2018 |
Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis.
Topics: Aged; Dementia; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Risk Factors; Thiazolidi | 2016 |
1 trial available for metformin and Amentia
| Article | Year |
|---|---|
Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; | 2011 |
19 other studies available for metformin and Amentia
| Article | Year |
|---|---|
Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Mid | 2022 |
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record | 2022 |
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record | 2022 |
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record | 2022 |
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record | 2022 |
Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study.
Topics: Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulins; | 2023 |
Metformin protects against dementia in diabetes.
Topics: Dementia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2023 |
Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
Topics: Aged; Biomarkers; Dementia; Diabetes Mellitus; Drug Administration Schedule; Female; Glycated Hemogl | 2020 |
Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
Topics: Aged; Aged, 80 and over; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase I | 2020 |
Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort.
Topics: Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; | 2020 |
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.
Topics: Aged; Databases, Factual; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; D | 2021 |
[Vitamin B
Topics: Adult; Age Factors; Aged; Dementia; Female; Humans; Longitudinal Studies; Male; Mass Screening; Metf | 2018 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycate | 2017 |
Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; H | 2017 |
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; L | 2018 |
Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts.
Topics: Alzheimer Disease; Brain; Cognition; Cohort Studies; Dementia; Humans; Hypoglycemic Agents; Incidenc | 2019 |
Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
Topics: Age Factors; Aged; Black or African American; Comorbidity; Dementia; Diabetes Mellitus, Type 2; Fema | 2019 |
Metformin and Sulfonylurea Use and Risk of Incident Dementia.
Topics: Age Factors; Aged; Databases, Factual; Dementia; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2019 |
Effect of pioglitazone medication on the incidence of dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; | 2015 |
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dementia; Depr | 2017 |